Core Viewpoint - The approval of Geri embryo culture medium by the National Medical Products Administration (NMPA) in China marks a significant milestone for the company, establishing it as the first Chinese enterprise to obtain FDA, CE, TGA, and NMPA certifications for high-end assisted reproductive materials [1][2]. Group 1: Product Approval and Certifications - The Geri embryo culture medium received its Class III medical device registration certificate from the NMPA on February 25, 2026 [1]. - Prior to this approval, the Geri embryo culture medium had already obtained certifications from the European Union (CE), the U.S. Food and Drug Administration (FDA), and the Australian Therapeutic Goods Administration (TGA) [1]. Group 2: Technological Advantages - The core technology of the Geri embryo culture medium addresses fertility challenges for older patients through a systematic solution, featuring a "triple antioxidant protection network" that effectively mitigates oxidative stress in older embryos [2]. - The product simplifies laboratory operations and ensures a stable culture environment by incorporating human serum albumin and ultra-long-term stability [2]. Group 3: Clinical Impact and Market Position - International clinical validation indicates that the Geri embryo culture medium, when combined with the Geri wet incubator and AI embryo assessment system, significantly enhances the rates of high-quality blastocysts and clinical pregnancy [2]. - The approval signifies a critical transition from technology introduction to localized production, filling a gap in the domestic market for high-end assisted reproductive consumables [2]. - The company has established a strong presence across most PGT licensed institutions in China and operates numerous localized laboratories, creating a sustainable ecological barrier for continuous innovation [2].
贝康医疗-B(02170)：Geri胚胎培养液(Gems胚胎培养液系列产品之一)获国家药监局颁发医疗器械注册证